Results 111 to 120 of about 3,429 (181)
Protein Science, Volume 35, Issue 9, September 2026.Abstract Somatic mutations and antibody clone selection occur in B‐cell hyper‐evolution over extremely brief periods of time. Herein, we developed a technique for antibody screening by immunizing alpacas with antigens and observing antibody sequence transitions over time, a method we named Tracking the Evolution of Antibodies over time.
Yoko Akazawa‐Ogawa +7 more
wiley +1 more source
The Plant Genome, Volume 19, Issue 3, September 2026.Abstract Camptothecin (CPT), a plant‐derived monoterpene indole alkaloid first identified in Camptotheca acuminata, is a drug precursor widely used for cancer chemotherapeutics. However, the full set of genes responsible for CPT biosynthesis remains unclear, hindering efforts to elucidate the complete pathway or establish biosynthetic production of CPT
Shenqi Wang +6 more
wiley +1 more source
Advanced Science, Volume 13, Issue 43, 3 August 2026.This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander +14 more
wiley +1 more source
Clinical Advances in Breast Cancer: A Comprehensive Overview of Full‐Course Disease Management
Cancer Innovation, Volume 5, Issue 4, August 2026.This review provides a comprehensive overview of clinical advances in breast cancer, highlighting subtype‐specific therapeutic paradigms. It underscores the full‐cycle integration of innovative therapies, as well as the growing role of biomarker‐guided strategies in advancing precision medicine.
Xuenan Peng, Yujing Tan, Fei Ma
wiley +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source
Resistance to HER2-targeted therapy
Research in Molecular Medicine, 2013 Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment.
Reza Valadan +3 more
doaj
Clinical Case Reports, Volume 14, Issue 8, August 2026.This flowchart systematically outlines the full diagnostic and therapeutic pathway of mammary Paget's disease with ipsilateral multifocal breast cancer, covering preoperative radiological assessment, postoperative histopathological confirmation of inter‐lesional molecular heterogeneity, individualized multimodal treatment, recurrence‐free follow‐up ...
Hongyu Cheng, Jiayin Tang, Chang Yao
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Serpentine supravenous hyperpigmentation (SSH) is a rare dermatological complication of intravenous chemotherapy characterized by linear hyperpigmented streaks along superficial veins. Bullous SSH represents an exceptionally rare variant with only a few previously reported cases in the literature. We report the case of a 50‐year‐old woman with
Gayathri R. Nair +5 more
wiley +1 more source
Cancer Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Breast cancer is the most common malignancy in women, and its incidence is increasing worldwide. Type 2 diabetes mellitus (T2DM) is a significant comorbidity in patients with breast cancer that negatively affects prognosis. Metformin, a first‐line antidiabetic drug, has been suggested to possess antineoplastic properties. This study
Ensiyeh Bahadoran +4 more
wiley +1 more source